Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2025
0mins
Source: Newsfilter
Company Liquidation Approval: Third Harmonic Bio, Inc. stockholders approved a Plan of Liquidation and Dissolution, with an expected initial distribution of approximately $5.30 to $5.35 per share in the third quarter of 2025.
THB335 Clinical Trial Update: The company reported positive results from a Phase 1 clinical trial of THB335, showing significant serum tryptase reduction and plans to initiate a sale process for THB335 and related intellectual property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
